Application of Pim1 small-molecule inhibitor in preparation of product for preventing and treating ankylosing spondylitis

Abstract

The invention belongs to the technical field of medical biology, and particularly relates to application of a Pim1 small-molecule inhibitor in preparation of a product for preventing and treating ankylosing spondylitis. A specific small-molecule inhibitor AZD1208 of Pim1 is used, the important effect of the Pim1 in Th17 differentiation is proved through in-vivo and in-vitro experiments, a situation that the Pim1 can be used as a target for blocking the Th17 differentiation and IL-17A secretion is proved, and the safety, the effectiveness and the feasibility of treatment of the AS by using the AZD1208 are verified. Compared with an IL-17A monoclonal antibody, pim1 treats the AS by blocking the Th17 differentiation, and is positioned at the upstream part of the action of the IL-17A monoclonal antibody on the aspect of the mechanism, so that a new target and a new way can be provided for treating the AS, and a new choice is provided for AS patients, especially patients with poor treatment effect of the IL-17A monoclonal antibody.

Description

technical field [0001] The invention belongs to the field of medical biotechnology, and in particular relates to the application of Pim1 small molecule inhibitors in the preparation of products for the prevention and treatment of ankylosing spondylitis. Background technique [0002] Ankylosing spondylitis (AS) is a common autoimmune disease. The incidence of AS is relatively high, about 0.2-0.54% in our country, and it is more likely to occur in young adults, with a male-to-female ratio of 2-3:1. The pathological features of AS are chronic progressive inflammation and pathological osteogenesis involving the axial bone joints. The main clinical manifestations are inflammatory low back pain and ankylosis of the axial bone joints. During the chronic progression of the disease, the patient's labor capacity gradually decreases. decline or even loss, seriously affecting the quality of life. Because AS cannot be cured completely, it has brought a heavy economic burden to the coun...

AI Technical Summary

Problems solved by technology

Although secukinumab has shown a certain therapeutic effect clinically, it still has poor effect on some AS patients.

In addition, secukinumab is expensive, and its use has caused a large economic burden to most patients, so its universality is not high

Images